Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Uncomplicated Urinary Tract Infection Market from 2024 to 2025?
The market size of simple urinary tract infections has seen impressive growth in the last few years. It is projected to escalate from $10.24 billion in 2024 to $10.98 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.2%. Factors contributing to the growth during the historic period include increased instances of kidney failure, a surge in bladder cancer cases, a rise in chronic kidney disease occurrences, wider usage of urinary catheters, and a growing prevalence of diabetes.
What Is the Projected Market Size of the Uncomplicated Urinary Tract Infection Market?
The market for simpler urinary tract infections is poised to experience robust growth in the upcoming years. It is expected to surge to $14.27 billion by 2029 with a compound annual growth rate (CAGR) of 6.8%. The growth escalation in the forecasted timeline can be linked with increased bacterial infections, an aging populace, higher sexual activity levels, growing instances of urinary tract infections, and a rise in contraceptive usage. Some of the main trends observed during this forecast period are telemedicine development, progress in telehealth solutions, the creation of innovative drugs, improvements in urinary tract infection treatments, and advancements in research and development.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23550&type=smp
Who are the Major Competitors in the Uncomplicated Urinary Tract Infection Market Outlook?
Major companies operating in the uncomplicated urinary tract infection market are Cardinal Health, Pfizer Inc., Bayer AG, AstraZeneca plc, GSK plc, Eli Lilly and Company, Siemens AG, Strykar Healthcare, John Hopkins Medicine, Shionogi & Co. Ltd., Sysmex Corporation, Bio-Rad Laboratories Inc, Cipla Inc., UTILITY therapeutics Ltd, Orchid Pharma Limited, ACON Labs, Sonika Lifesciences, Emergency Care BC, EB Medicine, Iterum Therapeutics PLC
What Is Fueling Growth in the Uncomplicated Urinary Tract Infection Market?
The uncomplicated urinary tract infection market is propelled by the surging cases of chronic kidney diseases. CKD, a persistent condition marked by a gradual loss of kidney function, leads to the accumulation of waste and fluid within the body. The rise in this disease is primarily attributed to the growing instances of diabetes. Persistently elevated blood sugar levels can lead to kidney damage, affecting their waste filtration efficiency. The immune system gets weakened by chronic kidney disease, raising the vulnerability to urinary tract infections. The poor functioning of kidneys can cause urine retention, providing a conducive environment for bacterial multiplication. For instance, Kidney Research UK reported in June 2023 that the adult kidney transplants in the UK due to chronic kidney disease rose from 2,863 in 2021 to 2,976 in 2023. Hence, the growth of the uncomplicated urinary tract infection market is driven by the rising cases of chronic kidney diseases. The uncomplicated urinary tract infection market is further expected to be boosted by the increasing instances of diabetes. Diabetes, a long-term metabolic disease, is characterized by heightened blood sugar levels resulting from either inadequate insulin production or ineffective insulin usage. Unhealthy lifestyle choices, such as poor diet and lack of physical exercise, contribute to the rising cases of diabetes. The increasing consumption of processed foods high in sugar, coupled with physical inactivity, has escalated obesity levels, thereby elevating the risk of developing type 2 diabetes. High blood sugar levels provide favorable conditions for bacterial growth in the urinary tract, thereby raising the infection incidence. Moreover, diabetes can compromise the immune system, making it more challenging for the body to combat infections, including UTIs. For instance, the Office for Health Improvement & Disparities (OHID) reported in March 2024 that the percentage of people with Type 1 diabetes receiving all eight care processes in England surged from 35.2% to 43.8% within a year. Consequently, the uncomplicated urinary tract infection market growth is driven by the increasing cases of diabetes.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=23550&type=smp
Which Uncomplicated Urinary Tract Infection Market Segments Are Growing the Fastest?
The uncomplicated urinary tract infection market covered in this report is segmented –
1) By Test Type: Urinalysis, Urine Cultures, Susceptibility Testing
2) By Drug: Penicillin And Combinations, Quinolones, Cephalosporin, Azoles And Amphotericin B, Nitrofurans, Other Drugs
3) By End-Users: Hospitals, Diagnostic Labs, Research Institutes
Subsegments:
1) By Urinalysis: Dipstick Tests, Microscopic Examination, Automated Urinalysis
2) By Urine Cultures: Agar Plate Culture, Broth Culture, Chromogenic Media
3) By Susceptibility Testing: Disk Diffusion Method, Automated Susceptibility Testing, Molecular Susceptibility Testing
Which Industry Trends Are Shaping the Future of the Uncomplicated Urinary Tract Infection Market?
Top firms that are part of the uncomplicated urinary tract infection (UTI) market are zeroing in their efforts on creating antibiotics to boost the efficacy of treatments and fight off bacteria that have become resistant to antibiotics. Antibiotics aim to do away with bacterial infections by either killing off or halting the growth of bacteria within the body. For example, in April 2024, Pivya (pivmecillinam) tablets were given the thumbs up by the Food and Drug Administration, a federal agency based in the US, for the treatment of uncomplicated UTIs in adult women. These tablets are designed to treat uncomplicated UTIs that are caused by susceptible strains of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus. Pivmecillinam, once ingested, becomes mecillinam – a beta-lactam antibiotic that takes aim at gram-negative bacteria by preventing the synthesis of bacterial cell walls.
Access The Full Report Here:
Which Countries Are Leading the Uncomplicated Urinary Tract Infection Market?
North America was the largest region in the uncomplicated urinary tract infection market in 2024. The regions covered in the uncomplicated urinary tract infection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23550
This Report Delivers Insight On:
1. How big is the uncomplicated urinary tract infection market, and how is it changing globally?
2. Who are the major companies in the uncomplicated urinary tract infection market, and how are they performing?
3. What are the key opportunities and risks in the uncomplicated urinary tract infection market right now?
4. Which products or customer segments are growing the most in the uncomplicated urinary tract infection market?
5. What factors are helping or slowing down the growth of the uncomplicated urinary tract infection market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model